U.S. Life Sciences Stock News

Latest FY 2025 Earnings Snapshot Diamondback Energy (FANG) has just closed out FY 2025 with Q4 revenue of US$3.8 billion and a basic EPS loss of US$5.08, compared with Q4 FY 2024 revenue of US$3.5 billion and basic EPS of US$3.67. Over the same period, trailing twelve month revenue moved from US$10.6 billion at the end of FY 2024 to US$14.9 billion at the end of FY 2025, while trailing EPS shifted from US$15.53 to US$5.73. With trailing net margin down from 31.4% to 11.1% and profits under...

Henry Schein (HSIC) has wrapped up FY 2025 with fourth quarter revenue of US$3.4 billion and basic EPS of US$0.86, alongside trailing twelve month revenue of US$13.2 billion and EPS of US$3.29 that frame the latest print in a broader context. The company has seen quarterly revenue move from US$3.2 billion in Q4 2024 to US$3.4 billion in Q4 2025, with basic EPS shifting from US$0.75 to US$0.86 over the same period. Trailing twelve month EPS moved from US$3.08 to US$3.29 as investors weigh...

Genworth Financial (GNW) has wrapped up FY 2025 with Q4 revenue of US$1.8 billion and a basic EPS loss of US$0.05 from continuing operations, while trailing twelve month revenue sits at US$7.3 billion and EPS at US$0.54. Over recent periods the company has seen quarterly revenue move in a tight band between US$1.8 billion and US$1.9 billion, with basic EPS ranging from a loss of roughly US$0.05 in Q4 2025 to a profit of about US$0.30 in Q3 2025. This pattern is prompting investors to focus on...

Claritev (CTEV) has just wrapped up FY 2025 with Q4 revenue of US$246.6 million and a basic EPS loss of US$4.88, alongside trailing 12 month revenue of US$965.4 million and a basic EPS loss of US$17.30. Over recent quarters, the company has seen revenue move from US$230.5 million in Q3 2024 to US$246.6 million in Q4 2025. Quarterly basic EPS has ranged from a loss of US$24.25 in Q3 2024 to a loss of US$3.81 to US$4.88 through 2025, setting a backdrop of significant revenue scale paired with...

Black Stone Minerals (BSM) just wrapped up FY 2025 with fourth quarter revenue of US$90.5 million and basic EPS of US$0.31, alongside trailing twelve month revenue of US$401.0 million and EPS of US$1.28 that frame the latest print in a fuller context. Over the past year, the company has seen trailing twelve month revenue move from US$427.0 million and EPS of US$1.15 in Q4 2024 to US$401.0 million and US$1.28 respectively by Q4 2025, while net income on the same basis went from US$241.9...

Valmont Industries (NYSE:VMI) announced a 13% increase to its quarterly dividend. The company appointed Paul Maass, an experienced agribusiness executive, to its Board of Directors. Valmont Industries, known for its infrastructure and agricultural solutions, is drawing fresh attention with a higher dividend and a board appointment that speaks directly to its core markets. For income focused investors, the 13% dividend move highlights a fresh data point on capital returns policy. The...

Myriad Genetics (MYGN) just closed FY 2025 with fourth quarter revenue of US$209.8 million and a quarterly loss of US$7.9 million, equivalent to basic EPS of a US$0.08 loss. Over recent periods the company has seen quarterly revenue move between US$195.9 million and US$213.1 million, while basic EPS has ranged from roughly breakeven in early FY 2025 to a much larger US$3.57 loss in the second quarter, reflecting a wide spread in earnings outcomes for shareholders. With trailing twelve month...

In recent weeks, Pagaya Technologies reported softer-than-expected first-quarter guidance but reiterated that it is seeing no operational slippage or credit stress, even as broader market volatility weighed on sentiment. Analysts have reaffirmed positive views on the company, arguing that its AI-driven underwriting platform and measured growth outlook remain intact despite short-term market noise. With analysts highlighting management’s reassurance about stable operations, we’ll now...

Perfect (PERF) has just wrapped up FY 2025 with Q4 revenue of US$18.1 million and basic EPS of US$0.01, set against trailing twelve month revenue of US$69.2 million and EPS of US$0.05. Over recent quarters the company has seen revenue move from US$15.9 million in Q4 FY 2024 to US$18.1 million in Q4 FY 2025, while quarterly EPS has ranged between about US$0.002 and US$0.025 across FY 2025. This gives investors a clearer view of how growth and profitability are interacting. With a trailing net...

In February 2026, Jumia Technologies AG reported its fourth-quarter and full-year 2025 results, with sales rising to US$61.4 million for the quarter and US$188.93 million for the year, while net losses narrowed to US$10.31 million and US$61.55 million respectively versus the prior year. The company also filed its 2025 Annual Report on Form 20-F with the SEC, offering investors a detailed view of how its pan-African marketplace, logistics network, and payment infrastructure are evolving as it...

Integer Holdings (ITGR) FY 2025 earnings snapshot Integer Holdings (ITGR) has wrapped up FY 2025 with fourth quarter revenue of $472.1 million and basic EPS of $1.39, rounding out a trailing twelve month EPS of $2.96 on $1.9 billion of revenue and net income of $102.8 million from ongoing operations. The company has seen quarterly revenue range from $437.4 million in Q1 2025 to $476.5 million in Q2 2025. Quarterly EPS moved from a Q1 loss of $0.66 to positive readings of $1.06, $1.13 and...

Targa Resources (NYSE:TRGP) announced a major build out of natural gas processing plants in the Permian Basin. The company is adding a new large scale NGL fractionator, Train 13, at its Mont Belvieu complex. Targa outlined additional growth projects, including carbon capture initiatives and AI driven technology upgrades across its system. The expansion is described as aimed at meeting rising energy demand tied to data centers and broader market needs. Targa Resources, a large midstream...

MediaAlpha FY 2025 Earnings Snapshot MediaAlpha (MAX) has wrapped up FY 2025 with fourth quarter revenue of US$291.2 million and basic EPS of US$0.56, alongside trailing twelve month revenue of about US$1.1 billion and EPS of US$0.46 that sit against earnings growth of 54.1% over the past year. Over the last few quarters, the company has seen revenue range from US$251.6 million to US$306.5 million per quarter. EPS swung from a loss of US$0.33 in Q2 2025 to a profit of US$0.26 in Q3 and...

Sotera Health (SHC) has put a full year of results on the table, with Q4 FY 2025 revenue of US$303.4 million and basic EPS of US$0.12, rounding out trailing 12 month revenue of about US$1.2 billion and EPS of US$0.27 that follows earnings growth of 75.8% over the past year. Over recent quarters the company has seen revenue move from US$254.5 million in Q1 FY 2025 to US$311.3 million in Q3 and US$303.4 million in Q4. Quarterly basic EPS has ranged from a loss of US$0.05 in Q1 to US$0.17 in Q3...

Expeditors International of Washington (EXPD) just wrapped up FY 2025 with fourth quarter revenue of US$2.9 billion and basic EPS of US$1.50, alongside net income of US$200.7 million. Together, these results set the tone for how the full year will be judged. Over recent quarters, the company has seen revenue range from US$2.7 billion to US$3.0 billion, while quarterly EPS moved between roughly US$1.35 and US$1.69. This gives investors a clearer view of how the top and bottom lines have...

Establishment Labs Holdings (NasdaqCM:ESTA) just wrapped FY 2025 with Q4 revenue of US$64.6 million and a basic EPS loss of US$0.09, alongside trailing twelve month revenue of US$211.1 million and a TTM basic EPS loss of US$1.72. The company has seen quarterly revenue move from US$40.2 million in Q3 2024 to US$64.6 million in Q4 2025, while quarterly basic EPS losses shifted from US$1.19 in Q4 2024 to US$0.09 in Q4 2025, setting up an earnings story where stronger top line figures are still...

Cogent Biosciences (NasdaqGS:COGT) has advanced its lead therapy bezuclastinib into a Phase 3 trial for systemic mastocytosis. The company has also filed a significant shelf registration that could be used to raise capital in the future. These updates highlight progress in Cogent Biosciences' clinical pipeline alongside preparations for potential funding needs. Cogent Biosciences enters this news cycle with its shares at $39.18 and very large 1 year returns, reflecting strong recent...

Upbound Group (UPBD) has wrapped up FY 2025 with Q4 revenue of US$1.2 billion and basic EPS of US$0.35, while trailing twelve month figures show revenue of US$4.7 billion and EPS of US$1.30 against a current share price around US$21.62. Over the past six quarters, the company has seen revenue move from US$1.08 billion in Q4 2024 to US$1.20 billion in Q4 2025, with quarterly EPS ranging between US$0.23 and US$0.57 along the way. This gives investors a clear view of how the top line and per...

Tarsus Pharmaceuticals (TARS) closed FY 2025 with fourth quarter revenue of US$151.7 million and a basic EPS loss of US$0.20, while net income excluding extra items came in at a loss of US$8.4 million. The company has seen quarterly revenue move from US$48.1 million and a basic EPS loss of US$0.61 in Q3 2024 to US$151.7 million and a loss of US$0.20 per share in Q4 2025. Trailing twelve month EPS stands at a loss of US$1.59 on revenue of US$451.4 million, outlining a picture where higher...

Great Lakes Dredge & Dock (GLDD) capped FY 2025 with Q4 revenue of US$256.5 million and basic EPS of US$0.19, rounding out a trailing twelve month picture that includes total revenue of US$888.3 million and EPS of US$1.10. Over the past few quarters, the company has seen revenue move from US$191.2 million in Q3 2024 to US$202.8 million in Q4 2024, then to US$242.9 million in Q1 2025 and US$195.2 million in Q3 2025, with quarterly EPS ranging from US$0.13 to US$0.50 over the same stretch. This...

Portillo's (PTLO) has wrapped up FY 2025 with fourth quarter revenue of US$185.7 million and basic EPS of US$0.08, alongside net income of US$6.1 million. This update gives investors an opportunity to reassess how the full year stacks up against its recent history. The company has seen quarterly revenue move from US$176.4 million in Q1 2025 to a range between US$181.4 million and US$188.5 million through the year, while EPS shifted between US$0.02 and US$0.13, giving a mixed read on profit...

China Yuchai International (NYSE:CYD) has just posted its FY 2025 first half numbers, with revenue of C¥13.8b and basic EPS of C¥9.75, setting the tone for a year in which investors are closely tracking how earnings and sales are holding up. The company has seen revenue move from C¥10.3b in the first half of 2024 to C¥13.8b in the first half of 2025, while basic EPS went from C¥5.88 to C¥9.75 over the same period. With trailing 12 month EPS at C¥14.32 on revenue of C¥24.7b, the results put...

Octave Specialty Group (OSG) just posted its FY 2025 numbers with Q4 total revenue of US$66.9 million and a basic EPS loss of US$0.66, while on a trailing twelve month basis revenue came in at US$251.2 million and EPS at a loss of US$2.09. The company has seen quarterly revenue move from US$65.2 million in Q4 FY 2024 to US$66.9 million in Q4 FY 2025, with basic EPS shifting from a loss of US$0.46 to a loss of US$0.66 over the same period. This sets the stage for investors to focus squarely on...

If you are wondering whether Jones Lang LaSalle is priced attractively today, a good starting point is understanding what the recent share moves are really telling you about value and risk. The stock last closed at US$310.97, after a 7 day return of 8.4%, a 30 day return showing a 12.2% decline, and returns of a 7.4% decline year to date and 17.1% over the past year, with longer term returns of 78.2% over 3 years and 74.5% over 5 years. Recent news around Jones Lang LaSalle has focused on...